Neuronetics Posts 86% Revenue Surge in Q4 2025, Names New CEO
Event summary
- Neuronetics reported $41.8M in Q4 2025 revenue, up 86% YoY, driven by Greenbrook clinic acquisition.
- Full-year 2025 revenue hit $149.2M, a 99% increase from 2024.
- Dan Reuvers appointed as President and CEO effective March 23, 2026.
- Company expects 2026 revenue between $160M and $166M.
- Collaboration with Compass Pathways on COMP360 psilocybin for treatment-resistant depression.
The big picture
Neuronetics' strong financial performance in 2025 highlights the strategic value of its Greenbrook acquisition, positioning it as a vertically integrated player in the mental health sector. The appointment of Dan Reuvers, with his extensive medical device leadership experience, signals a focus on scaling commercial healthcare businesses. The collaboration with Compass Pathways on psilocybin therapy underscores the company's push into innovative treatments for treatment-resistant depression, aligning with broader industry trends toward advanced neurohealth therapies.
What we're watching
- Integration Challenges
- How Neuronetics will manage the operational and financial integration of Greenbrook clinics to sustain growth momentum.
- Regulatory Approvals
- Whether Compass Pathways' COMP360 psilocybin will receive FDA approval by year-end 2026, impacting Neuronetics' strategic offerings.
- Leadership Impact
- The pace at which Dan Reuvers can drive operational efficiency and revenue growth in his new role as CEO.
Related topics